Market Overview

Echo Therapeutics Gets Fresh Patent For Non-Invasive Sensing Technology


Echo Therapeutics, Inc. (Nasdaq: ECTE) disclosed a fresh patent covering its system, as well as, methods for transdermal monitoring of analytes. This included glucose and other substances.

Echo Therapeutics said it got a notice that its patent application entitled "Transdermal Analyte Monitoring System and Methods for Analyte Detection" was granted by Japan and will expire in 2028.

According to the company, this is a divisional patent that illustrated a system utilizing a sensor and a hydrogel with a specific formulation that work together to allow detection of glucose, lactate or other substances. The company added that the allowance was significant in that it offered system level protection matching the design of Echo's NextGen system.

Echo Therapeutics President and CEO, Scott Hollander, commented, "This patent, along with the other previously announced Japanese patents, allows us to aggressively pursue business development opportunities that were not previously available in Japan."

He added, "With the addition of this patent we now have protection in Japan covering our CGM system as opposed to its individual components. We continue to invest in our global IP position in strategically targeted territories for applications of both current and future applications of our technology."

In the pre-market on Wednesday, the stock traded 9.5 percent higher.

Posted-In: Biotech News FDA General


Related Articles (ECTE)

View Comments and Join the Discussion!

Voyager Therapeutics Reveals Interim Phase 1b Surgical Results For VY-AADC01 In Advanced Parkinson's Disease

The Market In 5 Minutes: Elon Musk's Trillion-Dollar Bet